



Nexeon[®]

Decellularized Femoral Artery

Clinical Overview Nexeon is a decellularized vascular allograft intended for use as a conduit for blood flow in the peripheral vasculature.

- Applications**
- Arteriovenous Access for hemodialysis
 - Peripheral Vascular Disease (PVD) bypass
 - Peripheral Vascular Reconstruction

- Features & Benefits**
- **Long-term Patency***: Matrancell[®] decellularization reduces vessel stenosis and improves long-term patency by lowering risk of inflammation, thrombosis, and neointimal hyperplasia.^{1,2}
 - **Infection Resistance**: A preferred choice for infected sites and patients at risk of infection as vascular allografts are reported to have low incidence of infection.³⁻⁷
 - **Natural Healing and Integration***: A biohospitable matrix that supports cellular repopulation and proliferation with the appropriate native cells in the patient, fostering graft integration and long-term function.^{1,2,8,9}
 - **Early Access***: Graft can be accessed for hemodialysis within two weeks of implantation – at least 6X faster than an arteriovenous fistula.^{1,10}
 - **Proven Biomechanical Performance**: Demonstrates strength and flexibility comparable to native and cryopreserved tissue, backed by rigorous ISO-standard testing.^{1,11}
 - **Unmatched Quality**: Stringent graft selection and careful processing eliminate concerns of sudden diameter changes or kinking, preserving hemodynamics which could help improve graft patency.²
 - **Medical-Grade Safety**: Maintains the highest level of sterility while preserving biomechanical strength and physiologic integrity.^{1,2,11,12}
 - **Optimized for Surgeons**: Provides a familiar handling experience with compliance and suturability similar to native tissue. Available in a range of lengths and diameters to best match patient anatomy and meet surgical needs.^{1,11}
 - **Off-the-Shelf Convenience**: Room temperature storage eliminates the need for liquid nitrogen (LN₂) and ultra-cold freezers, streamlining OR logistics and improving efficiency.

**Based on a preclinical in vivo animal study.¹ Results in animals may not be representative of results in humans.*





Nexeon® Decellularized Femoral Artery

Room temperature storage (15° C-30° C), 5-year shelf life

Size	Order Code
Length: >30 cm Outer Diameter Range: 4 mm-10 mm	DFA>30

*Not all order codes are available and/or licensed in every country.
Please consult with your distributor or LifeNet Health Customer Experience for availability.*

Instructions for use available at [LifeNetHealth.org/IFU](https://www.lifenethealth.org/IFU)

References:

1. Data on file LifeNet Health® ES-19-076.
2. Data on file LifeNet Health® PQ-21-078.
3. Bossi, M., Tozzi, M., Franchin, M., Ferraro, S., Rivolta, N., Ferrario, M., Guttadauro, C., Castelli, P., & Piffaretti, G. (2017). Cryopreserved human allografts for the reconstruction of aortic and peripheral prosthetic graft infection. *Annals of Vascular Diseases*, 10(4), 391-397. doi: 10.3400/avd.oa.17-00068
4. Castier, Y., Francis, F., Cerceau, P., Besnard, M., Albertin, J., Foulhe, L., Cerceau, O., Albaladejo, P. & Lesèche, G. (2005). Cryopreserved arterial allograft reconstruction for peripheral graft infection. *Journal of vascular surgery*, 41(1), 30-37. <https://doi.org/10.1016/j.jvs.2004.09.025>
5. Harlander-Locke, M.P., Harmon, L.K., Lawrence, P.F., Oderich, G.S., McCready, R.A., Morasch, M.D., Feezor, R.J. & Vascular Low-Frequency Disease Consortium. (2014). The use of cryopreserved aortoiliac allograft for aortic reconstruction in the United States. *Journal of vascular surgery*, 59(3), 669-674. <https://doi.org/10.1016/j.jvs.2013.09.009>
6. Madden, R. L., Lipkowitz, G. S., Browne, B. J., & Kurbanov, A. (2004). Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access. *Annals of vascular surgery*, 18(4), 453-458. <https://doi.org/10.1007/s10016-004-0055-0>
7. Mousavi, S. R., Moatamedi, M. R. K., & ME AKBARI, M. (2011). Comparing frozen saphenous vein with Gore-tex in vascular access for chronic hemodialysis. *Hemodialysis International*, 15(4), 559-562. <https://doi.org/10.1111/j.1542-4758.2011.00578>
8. Data on file LifeNet Health® PQ-11-005.
9. Data on file LifeNet Health® ES-19-076Add1.
10. Bylsma, L. C., Gage, S. M., Reichert, H., Dahl, S. L. M., & Lawson, J. H. (2017). Arteriovenous fistulae for haemodialysis: a systematic review and meta-analysis of efficacy and safety outcomes. *European journal of vascular and endovascular surgery*, 54(4), 513-522. <https://doi.org/10.1016/j.jevs.2017.06.024>
11. Data on file LifeNet Health® ES-19-064.
12. Data on file LifeNet Health® PQ-10-008.

